Radiation Dose of the P-Glycoprotein Tracer 11C-Laniquidar.

Resistance to current drug therapy is an important issue in the treatment of epilepsy. Inadequate access of central nervous system drugs to their targets in the brain may be caused by overexpression or overactivity of multidrug transporters, such as P-glycoprotein (P-gp), at the blood-brain barrier. Laniquidar, an inhibitor of P-gp, has been labeled with (11)C for use in PET studies of P-gp expression in humans. Given potential interspecies differences in biodistribution, the purpose of this study was to ensure safe use of (11)C-laniquidar by determining the dosimetry of (11)C-laniquidar using whole-body PET studies.METHODS: Six healthy volunteers were subjected to a series of 10 whole-body PET scans within approximately 70 min. Five blood samples were taken during the series.RESULTS: High uptake of (11)C-laniquidar was seen in liver, spleen, kidneys, and lung, whereas brain uptake was low. The effective dose for (11)C-laniquidar was 4.76 ± 0.13 and 3.69 ± 0.01 μSv·MBq(-1) for women and men, respectively.CONCLUSION: Biodistribution and measured effective dose indicate that (11)C-laniquidar is a safe tracer for PET imaging, with a total dose of about 2 mSv for a brain PET/CT protocol.

Froklage, Femke E (författare)
van Lingen, Arthur (författare)
Reijneveld, Jaap C (författare)
Hendrikse, N Harry (författare)
Windhorst, Albert D (författare)
Schuit, Robert C (författare)
Eriksson, JonasVU university medical center Amsterdam(Swepub:uu)joeri542 (författare)
Lammertsma, Adriaan A (författare)
Huisman, Marc C (författare)
VU university medical center Amsterdam (creator_code:org_t)

Ingår i:Journal of Nuclear Medicine: Society of Nuclear Medicine54:12, s. 2101-21030161-55051535-56672159-662X

Av författaren/redakt...: Postnov, Andrey; Froklage, Femke ...; van Lingen, Arth ...; Reijneveld, Jaap ...; Hendrikse, N Har ...; Windhorst, Alber ...; visa fler...; Schuit, Robert C; Eriksson, Jonas; Lammertsma, Adri ...; Huisman, Marc C; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Neurologi

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.